Trial
NCT03722108
Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
UNICANCER
Collaborators
Bayer
Condition
Adenocarcinoma of the Stomach
Intervention
Regorafenib and Irinotecan
Why stopped
Unfavorable benefit-risk balance in the experimental arm following the IDMC for intermediate efficacy and safety analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-10-16